Division of Pharmacy, The University of Texas MD Anderson Cancer Centergrid.240145.6, Houston, Texas, USA.
Department of Infectious Diseases and Employee Health, The University of Texas MD Anderson Cancer Centergrid.240145.6, Houston, Texas, USA.
Antimicrob Agents Chemother. 2021 Nov 17;65(12):e0123021. doi: 10.1128/AAC.01230-21. Epub 2021 Sep 27.
Posaconazole (POS) appears to have dose-proportional pharmacokinetics; however, there is a paucity of real-life data. We retrospectively evaluated 67 patients with hematologic cancer who had POS dose increases from 300 mg/day to either 400 mg/day ( = 52) or 300 mg twice daily (BID) ( = 15) and for whom POS serum levels were measured. Median POS levels were 840 ng/ml, 1,625 ng/ml, and 2,710 ng/ml for the dosages of 300 mg/day, 400 mg/day, and 300 mg BID, respectively. Significant interpatient variability in serum levels was noted.
泊沙康唑（POS）的药代动力学似乎呈剂量比例关系，但实际数据较少。我们回顾性评估了 67 例血液系统恶性肿瘤患者，这些患者的泊沙康唑剂量从 300mg/天增加到 400mg/天（ = 52）或 300mg 每日两次（BID）（ = 15），并对这些患者的泊沙康唑血清水平进行了检测。300mg/天、400mg/天和 300mg BID 的泊沙康唑血清水平中位数分别为 840ng/ml、1625ng/ml和 2710ng/ml。观察到血清水平存在显著的个体间变异性。
